Impact Factor
3.41
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.55
907 total citations
h5-index
37
h5 depth signal
Cited share
63.9%
244 of 382
Total citations
907
Citation footprint
Metric signal
2.96
External metric anchor
Self-citation
10.1%
92 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
900
United Kingdom
240
Netherlands
207
Canada
174
Denmark
153
Citing Fields of Research
Medical Ethics
550
Pharmacology & Toxicology
427
Patient Care
322
Statistical Methods
271
Cardiology
205
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
5,464
Articles tracked across the journal lifetime
Indexed publication set
382
244 cited publications
Last 12 months
261
21.8 publications/month
Open access share
53.3%
139 OA publications in the last year
Leading citing country
United States
900 citing publications
Leading citing field
Medical Ethics
550 citing publications
Latest tracked publication
18 October 2026
10 recent records available
Coverage & Indexing History
v10n1, Jan.-Feb. 2001-
v10n1, Jan.-Feb. 2001-
Active Coverage
Research Focus & Classification
Indexed Subjects
Medical Ethics
Statistical Methods
Patient Care
Pharmacology & Toxicology
Obstetrics/Gynecology
Cardiology
Broad Categories
Drug Therapy
Epidemiology
Medical Ethics
Statistical Methods
Cardiology
Obstetrics/Gynecology
Virology
Anesthetic & Pain Medicine
MeSH Descriptors
Drug Utilization
Drug-Related Side Effects and Adverse Reactions
Epidemiologic Methods
Epidemiology
Pharmacology, Clinical
Product Surveillance, Postmarketing
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1002/pds.70510
Open DOI
Selective Prescribing of First‐Line SGLT2 Inhibitor and GLP ‐1 RA in Adults With Severe Mental Illness and Type 2 Diabetes
Purpose: SGLT2 inhibitors (SGLT2i) and GLP‐1 receptor agonists (GLP‐1 RA) provide cardiovascular (CV) benefits, but their first‐line use among adults with severe mental illness (SMI) is not well characterized. We evaluated selective pres...
02
DOI 10.1002/pds.70507
Open DOI
Evaluating Darbepoetin Treatment Strategies for Managing Anaemia in Haemodialysis Patients: Effects on All‐Cause Mortality From a Target Trial Emulation Using Electronic Health Record Data
Purpose: Anaemia is a common complication of chronic kidney disease, often treated with erythropoiesis‐stimulating agents (ESAs), but the optimal haemoglobin (Hb) target remains uncertain. Using electronic health records, we emulated a t...
03
DOI 10.1002/pds.70485
Open DOI
Target Trial Emulation or Target Trial Approximation?
Target trial emulation has contributed to improvements in the design and interpretation of observational studies aimed at causal inference. By encouraging researchers to think explicitly about the design of a hypothetical randomized tria...
04
DOI 10.1002/pds.70508
Open DOI
Cancer Treatment During Pregnancy and Maternal and Infant Outcomes: A Descriptive Cohort Study Using a Japanese Claims Database
Purpose: To characterize cancer treatment during pregnancy and maternal and infant outcomes among women with cancer identified during pregnancy in Japan. Methods: In this descriptive cohort study, we used mother‐infant linkage data from ...
05
DOI 10.1002/pds.70505
Open DOI
Prescription Intervals of Medications for Chronic Use: A Cohort Study
Purpose: In deprescribing studies, a prescription‐free gap is typically used to determine if patients discontinued their treatment. An appropriate gap depends on the typical time between prescriptions during continued use. This work aims...
06
DOI 10.1002/pds.70504
Open DOI
Impact of COVID ‐19 Restrictions on Estimating Causal Effects: Fluoroquinolones and Tendon Rupture
Purpose: The COVID‐19 pandemic disrupted healthcare services, potentially affecting causal effect estimation using real‐world data. As a case study, we replicated a cohort study using Clinical Practice Research Datalink Aurum to evaluate...
07
DOI 10.1002/pds.70502
Open DOI
Temporal Trends in Janus Kinase Inhibitor ( JAKi ) Use Across Five European Countries: A DARWIN EU Network Study
Introduction: Janus kinase inhibitors (JAKi) are increasingly used for autoimmune conditions despite existing safety concerns. This study aims to estimate the incidence of new JAKi use over time and characterise users in Europe to suppor...
08
DOI 10.1002/pds.70501
Open DOI
High Burden and Phenotype‐Specific Variability of Pain Polypharmacy in Early Autoimmune Rheumatic Diseases: A 14‐Year Analysis
Background: Pain drives disability and medication use in autoimmune rheumatic diseases (ARDs), even when inflammation is controlled. The extent of pain‐related polypharmacy across ARDs and chronic overlapping pain conditions (COPCs) rema...
09
DOI 10.1002/pds.70291
Open DOI
Issue Information
10
DOI 10.1002/pds.70486
Open DOI
Long‐Term Treatment Patterns in Norwegian ADHD ‐Medicine Users: A Cohort Register‐Based Study With 5 Years of Follow‐Up, 2012–2021
Purpose: To improve interpretation of long‐term ADHD medication treatment trajectories in Norway by examining sex‐ and age‐specific persistence, distinguishing within‐substance product switching from active‐ingredient (ATC substance) swi...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Vol. 1, no. 1 (JAN-FEB 1992)19920228 Notice published Printed on acid-free paper